Scotiabank raises American Healthcare REIT price target on growth outlook

Scotiabank raised its AHR price target to $59 from $55 while keeping a Sector Outperform; the stock trades at $52.98 after an 89% gain over the past year. Scotiabank forecasts FFOPS growth of 19% in 2026 and 11% in 2027 and assumes $600M of additional acquisitions in both 2026 and 2027; InvestingPro shows 18% revenue growth for 2026. AHR reported Q4 2025 EPS of $0.06 and revenue of $604.08M, announced an at-the-market equity program permitting up to $1.75B of common stock, and generated FAD of $0.37 (Citizens estimate $0.40).

Analysis

Management leaning on equity-capital optionality to fund external growth creates an execution-sensitive story: upside accrues only if deal pace and purchase economics are both accretive after incremental leverage and higher recurring capex. That makes AHR a call on M&A execution and funding spreads, not just organic operations; counterparties (regional operators, private equity consolidators) will benefit if acquisition multiples remain rational.

Interest-rate and reimbursement pathways are the most important macro knobs — a modest rise in long-term rates or a tightening of public-payor rules would compress cap rates and elongate deal payback well before higher FFO run-rate materializes. Operationally, labor and facility capex inflation are second-order margin levers; if staffing shortages persist, the put-through to FFO growth is non-linear and will re-rate the stock relative to larger, better-capitalized peers.

The near-term catalyst set is narrow: quarterly FFO prints and any announced incremental buy-and-build activity. Measured positions that monetize a binary acquisition beat or miss are preferable to naked long exposure; volatility will be driven more by capital-allocation news and rate moves than same-store operating beats. Monitor leverage metrics and coverage ratios post-deal as the primary read-through for upside preservation.

Key Decisions for Investors

• Tactical long via options: Allocate a small tranche (<=5% of intended equity exposure) to a 9–15 month AHR call-spread sized to cost no more than 4–6% of notional. Rationale: captures asymmetric upside if management accelerates accretive M&A; max loss = premium (4–6%), target absolute upside = 18–30% on deal execution.
• Relative-value pair: Go long AHR / short VTR on a delta-neutral FFO basis (size by expected 2026 FFO per share). Timeframe 6–12 months. R/R: seeks 15–25% convergence if AHR’s execution premium proves durable; cut losses if combined position moves >15% adverse or leverage metrics deteriorate.
• Hedge core exposure: If owning AHR stock, buy 12-month protective puts equal to ~20% of position notional (or buy downside put spreads) to cap tail risk from rate shock or reimbursement changes. Cost should be treated as insurance—acceptable drag <200bp annualized if macro risk rises.
• Event-lite short: If conviction that market has priced in flawless M&A execution, consider shorting WELL-sized name versus AHR long to express disappointment risk; keep time horizon to next two quarterly FFO prints and use 10–15% stop-loss to limit campaign risk.